Loading...
Minnesota Criminal Justice Statute Service
Search
Subscribe to Updates
Reports
Statute Change Report
About
Glossary
Quick Search
152.02.4
Statute ID:
18629
Statute Function ID:
38002
Drugs - Schedules Of Controlled Substances - Definitions - Schedule III
In Effect
New Search
Refine Search
Back to Results
Function Details
History
Text
Details are only available for Penalty and Charging Statutes.
Statute Number:
152.02.4
Enactment Date:
May 30, 2023
Effective Date:
May 31, 2023
Expiration Date:
Repealed?:
No
Summary Text:
Drugs - Schedules Of Controlled Substances - Definitions - Schedule III
Statute ID:
18629
Created:
May 30, 2023 by mnjis.legal.analyst@state.mn.us
Updated:
May 30, 2023 by mnjis.legal.analyst@state.mn.us
Last Update Action:
Added
Legal Analyst Comment:
Amended C63 Art 8 S2; Effective DAE - 05/31/2023
Summary Text:
Drugs - Schedules Of Controlled Substances - Definitions - Schedule III
Link to MN Statute Text:
https://www.revisor.leg.state.mn.us/stats/152/02.html
Legislative Session:
2023 - Regular
Session Law Text?:
No
Statute text last updated on:
May 30, 2023
(a) Schedule III: consists of the substances listed in this subdivision. (b) Unless specifically excepted or unless listed in another schedule, any material, compound, mixture, or preparation which contains any quantity of the following substances having a potential for abuse associated with a stimulant effect on the central nervous system, including its salts, isomers, and salts of such isomers whenever the existence of such salts, isomers, and salts of isomers is possible within the specific chemical designation: (1) benzphetamine; (2) chlorphentermine; (3) clortermine; (4) phendimetrazine. (c) Depressants. Unless specifically excepted or unless listed in another schedule, any material, compound, mixture, or preparation which contains any quantity of the following substances having a potential for abuse associated with a depressant effect on the central nervous system: (1) any compound, mixture, or preparation containing amobarbital, secobarbital, pentobarbital or any salt thereof and one or more other active medicinal ingredients which are not listed in any schedule.; (2) any suppository dosage form containing amobarbital, secobarbital, pentobarbital, or any salt of any of these drugs and approved by the food and drug administration for marketing only as a suppository.; (3) any substance which contains any quantity of a derivative of barbituric acid, or any salt of a derivative of barbituric acid, except those substances which are specifically listed in other schedules. (4) any drug product containing gamma hydroxybutyric acid, including its salts, isomers, and salts of isomers, for which an application is approved under section 505 of the federal Food, Drug, and Cosmetic Act; (5) any of the following substances: (i) chlorhexadol; (ii) ketamine, its salts, isomers and salts of isomers; (iii) lysergic acid; (iv) lysergic acid amide; (v) methyprylon; (vi) sulfondiethylmethane; (vii) sulfonenthylmethane; (viii) sulfonmethane; (ix) tiletamine and zolazepam and any salt thereof; (x) embutramide; (xi)Perampanel [2-(2-oxo-1-phenyl-5-pyridin-2-yl-1,2-Dihydropyridin-3-yl) benzonitrile]. (d) Nalorphine. (e) Narcotic drugs. Unless specifically excepted or unless listed in another schedule, any material, compound, mixture, or preparation containing any of the following narcotic drugs, or their salts calculated as the free anhydrous base or alkaloid, in limited quantities as follows: (1) not more than 1.80 grams of codeine per 100 milliliters or not more than 90 milligrams per dosage unit, with an equal or greater quantity of an isoquinoline alkaloid of opium.; (2) not more than 1.80 grams of codeine per 100 milliliters or not more than 90 milligrams per dosage unit, with one or more active, nonnarcotic ingredients in recognized therapeutic amounts.; (3) not more than 1.80 grams of dihydrocodeine per 100 milliliters or not more than 90 milligrams per dosage unit, with one or more active, nonnarcotic ingredients in recognized therapeutic amounts.; (4) not more than 300 milligrams of ethylmorphine per 100 milliliters or not more than 15 milligrams per dosage unit, with one or more active, nonnarcotic ingredients in recognized therapeutic amounts.; (5) not more than 500 milligrams of opium per 100 milliliters or per 100 grams, or not more than 25 milligrams per dosage unit, with one or more active, nonnarcotic ingredients in recognized therapeutic amounts.; (6) not more than 50 milligrams of morphine per 100 milliliters or per 100 grams with one or more active, nonnarcotic ingredients in recognized therapeutic amounts.; (f) Anabolic steroids, human growth hormone, and chorionic gonadotropin. (1) Anabolic steroids, for purposes of this subdivision, means any drug or hormonal substance, chemically and pharmacologically related to testosterone, other than estrogens, progestins, corticosteroids, and dehydroepiandrosterone, and includes: (i) 3[beta],17[beta]-dihydroxy-5[alpha]-androstane; (ii) 3[alpha],17[beta]-dihydroxy-5[alpha]-androstane; (iii) androstanedione (5[alpha]-androstan-3,17-dione); (iv) 1-androstenediol (3[beta],17[beta]-dihydroxy-5[alpha]-androst-l-ene; (v) 3[alpha],17[beta]-dihydroxy-5[alpha]-androst-1-ene); (vi) 4-androstenediol (3[beta],17[beta]-dihydroxy-androst-4-ene); (vii) 5-androstenediol (3[beta],17[beta]-dihydroxy-androst-5-ene); (viii) 1-androstenedione (5[alpha]-androst-1-en-3,17-dione); (ix) 4-androstenedione (androst-4-en-3,17-dione); (x) 5-androstenedione (androst-5-en-3,17-dione); (xi) bolasterone (7[alpha],17[alpha]-dimethyl-17[beta]-hydroxyandrost-4-en-3-one); (xii) boldenone (17[beta]-hydroxyandrost-1,4-diene-3-one); (xiii) boldione (androsta-1,4-diene-3,17-dione); (xiv) calusterone (7[beta],17[alpha]-dimethyl-17[beta]-hydroxyandrost-4-en-3-one); (xv) clostebol (4-chloro-17[beta]-hydroxyandrost-4-en-3-one); (xvi) dehydrochloromethyltestosterone (4-chloro-17[beta]-hydroxy-17[alpha]-methylandrost-1,4-dien-3-one); (xvii) desoxymethyltestosterone (17[alpha]-methyl-5[alpha]-androst-2-en-17[beta]-ol); (xviii) [delta]1-dihydrotestosterone- (17[beta]-hydroxy-5[alpha]-androst-1-en-3-one); (xix) 4-dihydrotestosterone (17[beta]-hydroxy-androstan-3-one); (xx) drostanolone (17[beta]hydroxy-2[alpha]-methyl-5[alpha]-androstan-3-one); (xxi) ethylestrenol (17[alpha]-ethyl-17[beta]-hydroxyestr-4-ene); (xxii) fluoxymesterone (9-fluoro-17[alpha]-methyl-11[beta],17[beta]-dihydroxyandrost-4-en-3-one); (xxiii) formebolone (2-formyl-17[alpha]-methyl-11[alpha],17[beta]-dihydroxyandrost-1,4-dien-3-one); (xxiv) furazabol (17[alpha]-methyl-17[beta]-hydroxyandrostano[2,3-c]-furazan)13[beta]-ethyl-17[beta] -hydroxygon-4-en-3-one; (xxv) 4-hydroxytestosterone (4,17[beta]-dihydroxyandrost-4-en-3-one); (xxvi) 4-hydroxy-19-nortestosterone (4,17[beta]-dihydroxyestr-4-en-3-one); (xxvii) mestanolone (17[alpha]-methyl-17[beta]-hydroxy-5[alpha]-androstan-3-one); (xxviii) mesterolone (1[alpha]-methyl-17[beta]-hydroxy-5[alpha]-androstan-3-one); (xxix) methandienone (17[alpha]-methyl-17[beta]-hydroxyandrost-1,4-dien-3-one); (xxxi) methasterone (2 alpha-17 alpha-dimethyl-5 alpha-androstan-17beta-ol-3-one) (xxxii) methenolone (1-methyl-17[beta]-hydroxy-5[alpha]-androst-1-en-3-one); (xxxiii) 17[alpha]-methyl-3[beta],17[beta]-dihydroxy-5[alpha]-androstane; (xxxiv) 17[alpha]-methyl-3[alpha],17[beta]-dihydroxy-5[alpha]-androstane; (xxxv) 17[alpha]-methyl-3[beta],17[beta]-dihydroxyandrost-4-ene; (xxxvi) 17[alpha]-methyl-4-hydroxynandrolone (17[alpha]-methyl-4-hydroxy-17[beta]-hydroxyestr-4-en-3-one); (xxxvii) methyldienolone (17[alpha]-methyl-17[beta]-hydroxyestra-4,9(10)-dien-3-one); (xxxviii) methyltrienolone (17[alpha]-methyl-17[beta]-hydroxyestra-4,9-11-trien-3-one); (xxxix) methyltestosterone (17[alpha]-methyl-17[beta]-hydroxyandrost-4-en-3-one); (xl) mibolerone (7[alpha],17[alpha]-dimethyl-17[beta]-hydroxyestr-4-en-3-one); (xli) 17[alpha]-methyl-[delta]1-dihydrotestosterone (17[beta]-hydroxy-17[alpha]-methyl-5[alpha]-androst-1-en-3-one); (xlii) nandrolone (17[beta]-hydroxyestr-4-en-3-one); (xliii) 19-nor-4-androstenediol (3[beta],17[beta]-dihydroxyestr-4-ene; (xliv) 3[alpha],17[beta]-dihydroxyestr-4-ene); 19-nor-5-androstenediol (3[beta],17[beta]-dihydroxyestr-5-ene; (xlv) 3[alpha],17[beta]-dihydroxyestr-5-ene); (xlvi) 19-nor-4,9(10)-androstadienedione (estra-4,9(10)-diene-3,17-dione); (xlvii) 19-nor-5-androstenedione (estr-5-en-3,17-dione); (xlviii) norbolethone (13[beta],17[alpha]-diethyl-17[beta]-hydroxygon-4-en-3-one); (xlix) norclostebol (4-chloro-17[beta]-hydroxyestr-4-en-3-one); (l) norethandrolone (17[alpha]-ethyl-17[beta]-hydroxyestr-4-en-3-one); (li) normethandrolone (17[alpha]-methyl-17[beta]-hydroxyestr-4-en-3-one); (lii) oxandrolone (17[alpha]-methyl-17[beta]-hydroxy-2-oxa-5[alpha]-androstan-3-one); (liii) oxymesterone (17[alpha]-methyl-4,17[beta]-dihydroxyandrost-4-en-3-one); (liv) oxymetholone (17[alpha]-methyl-2-hydroxymethylene-17[beta]-hydroxy-5[alpha]-androstan-3-one); (lv) prostanozol (17 beta-hydroxy-5 alpha-androstano[3,2-C]pryazole new text end (lvi) stanozolol (17[alpha]-methyl-17[beta]-hydroxy-5[alpha]-androst-2-eno[3,2-c]-pyrazole); (lvii)stenbolone (17[beta]-hydroxy-2-methyl-5[alpha]-androst-1-en-3-one); (lviii) testolactone (13-hydroxy-3-oxo-13,17-secoandrosta-1,4-dien-17-oic acid lactone); (lix) testosterone (17[beta]-hydroxyandrost-4-en-3-one); (lx) tetrahydrogestrinone (13[beta],17[alpha]-diethyl-17[beta]-hydroxygon-4,9,11-trien-3-one); (lxi) trenbolone (17[beta]-hydroxyestr-4,9,11-trien-3-one); lxii) any salt, ester, or ether of a drug or substance described in this paragraph. Anabolic steroids are not included if they are: (A) expressly intended for administration through implants to cattle or other nonhuman species; and(B) approved by the United States Food and Drug Administration for that use; (2) Human growth hormones. (3) Chorionic gonadotropin. (g) Hallucinogenic substances. Dronabinol (synthetic) in sesame oil and encapsulated in a soft gelatin capsule in a United States Food and Drug Administration approved product. (h) Any material, compound, mixture, or preparation containing the following narcotic drug or its salt: buprenorphine. (i) Marijuana, tetrahydrocannabinols, and synthetic cannabinoids. Unless specifically excepted or unless listed in another schedule, any natural or synthetic material, compound, mixture, or preparation that contains any quantity of the following substances, their analogs, isomers, esters, ethers, salts, and salts of isomers, esters, and ethers, whenever the existence of the isomers, esters, ethers, or salts is possible: (1) marijuana; (2) tetrahydrocannabinols naturally contained in a plant of the genus Cannabis, except that tetrahydrocannabinols do not include any material, compound, mixture, or preparation that qualifies as industrial hemp as defined in section 18K.02, subdivision 3; synthetic equivalents of the substances contained in the cannabis plant or in the resinous extractives of the plant; or synthetic substances with similar chemical structure and pharmacological activity to those substances contained in the plant or resinous extract, including but not limited to 1 cis or trans tetrahydrocannabinol, 6 cis or trans tetrahydrocannabinol, and 3,4 cis or trans tetrahydrocannabinol.
